QQ客服 官方微博 反馈留言

	Clinical significance of >= 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients
	Li, Wenbin; Song, Peng; Guo, Lei; Liu, Xiuyun; Guo, Changyuan; Ying, Jianming; Gao, Shugeng
	2019
卷号	10期号:2页码:175-182
关键词	Driver mutation non-small cell lung cancer programmed death ligand 1 smoking
ISSN号	1759-7706
DOI	10.1111/1759-7714.12929
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6345640
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li, Wenbin,Song, Peng,Guo, Lei,et al. Clinical significance of >= 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients[J],2019,10(2):175-182.
APA	Li, Wenbin.,Song, Peng.,Guo, Lei.,Liu, Xiuyun.,Guo, Changyuan.,...&Gao, Shugeng.(2019).Clinical significance of >= 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.,10(2),175-182.
MLA	Li, Wenbin,et al."Clinical significance of >= 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients".10.2(2019):175-182.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。